Analysts expect RXi Pharmaceuticals Corp (NASDAQ:RXII) to report ($0.20) earnings per share (EPS) for the current quarter, according to Zacks. Zero analysts have issued estimates for RXi Pharmaceuticals Corp’s earnings. RXi Pharmaceuticals Corp reported earnings per share of ($0.34) in the same quarter last year, which indicates a positive year over year growth rate of 41.2%. The company is scheduled to announce its next quarterly earnings results on Thursday, August 10th.
On average, analysts expect that RXi Pharmaceuticals Corp will report full-year earnings of ($0.74) per share for the current fiscal year. For the next fiscal year, analysts expect that the business will report earnings of ($0.57) per share. Zacks Investment Research’s EPS calculations are a mean average based on a survey of sell-side research analysts that follow RXi Pharmaceuticals Corp.
RXi Pharmaceuticals Corp (NASDAQ:RXII) last announced its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.20) by $0.08.
Shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) traded up 5.54% during mid-day trading on Monday, hitting $0.57. The company had a trading volume of 149,691 shares. The firm’s market cap is $12.57 million. The firm’s 50 day moving average is $0.66 and its 200-day moving average is $0.88. RXi Pharmaceuticals Corp has a 12-month low of $0.51 and a 12-month high of $3.27.
TRADEMARK VIOLATION WARNING: This article was originally published by Markets Daily and is the sole property of of Markets Daily. If you are reading this article on another website, it was stolen and republished in violation of United States & international copyright law. The legal version of this article can be read at https://www.themarketsdaily.com/2017/05/20/rxi-pharmaceuticals-corp-rxii-expected-to-announce-earnings-of-0-20-per-share.html.
An institutional investor recently bought a new position in RXi Pharmaceuticals Corp stock. Hudson Bay Capital Management LP acquired a new stake in shares of RXi Pharmaceuticals Corp (NASDAQ:RXII) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 214,406 shares of the biotechnology company’s stock, valued at approximately $153,000. Hudson Bay Capital Management LP owned approximately 3.25% of RXi Pharmaceuticals Corp at the end of the most recent quarter. Institutional investors and hedge funds own 7.42% of the company’s stock.
RXi Pharmaceuticals Corp Company Profile
RXi Pharmaceuticals Corporation is a clinical-stage ribonucleic acid (RNA) interference (RNAi) company developing therapeutics in dermatology and ophthalmology that address unmet medical needs. The Company’s development programs are based on its self-delivering RNAi (sd-rxRNA) platform and Samcyprone, a topical immunomodulator.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for RXi Pharmaceuticals Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for RXi Pharmaceuticals Corp and related companies with MarketBeat.com's FREE daily email newsletter.